NASDAQ:GLUE Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis $4.67 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$4.55▼$4.9250-Day Range$3.38▼$4.9552-Week Range$2.44▼$8.84Volume204,103 shsAverage Volume188,662 shsMarket Capitalization$235.89 millionP/E RatioN/ADividend YieldN/APrice Target$12.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Monte Rosa Therapeutics alerts: Email Address Monte Rosa Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside162.3% Upside$12.25 Price TargetShort InterestBearish6.70% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 3 Articles This WeekInsider TradingSelling Shares$6,166 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.92) to ($1.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.71 out of 5 starsMedical Sector699th out of 936 stocksBiological Products, Except Diagnostic Industry116th out of 154 stocks 3.4 Analyst's Opinion Consensus RatingMonte Rosa Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMonte Rosa Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Monte Rosa Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.70% of the float of Monte Rosa Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonte Rosa Therapeutics has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.Change versus previous monthShort interest in Monte Rosa Therapeutics has recently increased by 11.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMonte Rosa Therapeutics does not currently pay a dividend.Dividend GrowthMonte Rosa Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GLUE. Previous Next 2.9 News and Social Media Coverage News SentimentMonte Rosa Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Monte Rosa Therapeutics this week, compared to 1 article on an average week.Search Interest4 people have searched for GLUE on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Monte Rosa Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Monte Rosa Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,166.00 in company stock.Percentage Held by InsidersOnly 6.50% of the stock of Monte Rosa Therapeutics is held by insiders.Percentage Held by Institutions79.96% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Monte Rosa Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Monte Rosa Therapeutics are expected to grow in the coming year, from ($1.92) to ($1.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monte Rosa Therapeutics is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Monte Rosa Therapeutics is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMonte Rosa Therapeutics has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Monte Rosa Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Monte Rosa Therapeutics Stock (NASDAQ:GLUE)Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Read More GLUE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLUE Stock News HeadlinesJuly 23 at 1:51 AM | americanbankingnews.comComparing Monte Rosa Therapeutics (NASDAQ:GLUE) and Finch Therapeutics Group (NASDAQ:FNCH)July 18, 2024 | americanbankingnews.comAnalyzing TScan Therapeutics (NASDAQ:TCRX) and Monte Rosa Therapeutics (NASDAQ:GLUE)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 8, 2024 | globenewswire.comMonte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation DayJuly 8, 2024 | globenewswire.comMonte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation DayJune 27, 2024 | globenewswire.comMonte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160June 14, 2024 | globenewswire.comMonte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid ArthritisMay 30, 2024 | globenewswire.comMonte Rosa Therapeutics Announces Leadership Team PromotionsJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 30, 2024 | globenewswire.comMonte Rosa Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Aerovate Therapeutics (AVTE)May 21, 2024 | globenewswire.comMonte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel DiseaseMay 18, 2024 | uk.investing.comMonte Rosa Therapeutics sets public offering at $4.70 per shareMay 16, 2024 | globenewswire.comMonte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public OfferingMay 15, 2024 | globenewswire.comMonte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Monte Rosa Therapeutics Amidst Promising Drug Pipeline and Stable FinancialsMay 10, 2024 | finance.yahoo.comMonte Rosa Therapeutics Reports Q1 2024 Financial Results: A Detailed OverviewMay 9, 2024 | investorplace.comGLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Misses Revenue for Q1 2024See More Headlines Receive GLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:GLUE CUSIPN/A CIK1826457 Webwww.monterosatx.com Phone617-949-2643FaxN/AEmployees133Year FoundedN/APrice Target and Rating Average Stock Price Target$12.25 High Stock Price Target$16.00 Low Stock Price Target$11.00 Potential Upside/Downside+162.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-135,350,000.00 Net MarginsN/A Pretax Margin-12,674.91% Return on Equity-74.13% Return on Assets-49.14% Debt Debt-to-Equity RatioN/A Current Ratio4.82 Quick Ratio4.82 Sales & Book Value Annual Sales$1.06 million Price / Sales221.70 Cash FlowN/A Price / Cash FlowN/A Book Value$3.58 per share Price / Book1.30Miscellaneous Outstanding Shares50,512,000Free Float47,229,000Market Cap$235.89 million OptionableOptionable Beta1.38 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Markus Warmuth M.D. (Age 52)President, CEO & Director Comp: $901.35kDr. Owen B. Wallace Ph.D. (Age 55)Chief Scientific Officer Comp: $630.68kDr. Filip Janku M.D. (Age 49)Ph.D., Chief Medical Officer Comp: $658.66kMs. Jennifer ChampouxChief People & Operations OfficerDr. Sharon Townson Ph.D. (Age 49)Chief Technology Officer Dr. John C. Castle Ph.D. (Age 52)Chief Data & Information Officer Mr. Andrew FunderburkSenior VP and Head of IR & Strategic FinanceMr. Philip Nickson J.D. (Age 45)Ph.D., General Counsel Mr. Magnus Walter DPHILSenior Vice President of Drug DiscoveryMr. Edmund Dunn (Age 58)Vice President & Corporate Controller More ExecutivesKey CompetitorsSeres TherapeuticsNASDAQ:MCRBInvivydNASDAQ:IVVDKinnate BiopharmaNASDAQ:KNTEbluebird bioNASDAQ:BLUEKronos BioNASDAQ:KRONView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 15,845 shares on 7/26/2024Ownership: 0.218%Edmund DunnSold 1,610 sharesTotal: $6,166.30 ($3.83/share)Price T Rowe Associates Inc. MDBought 155,880 shares on 5/15/2024Ownership: 10.091%EntryPoint Capital LLCBought 15,893 shares on 5/14/2024Ownership: 0.031%Vanguard Group Inc.Bought 47,412 shares on 5/10/2024Ownership: 3.250%View All Insider TransactionsView All Institutional Transactions GLUE Stock Analysis - Frequently Asked Questions How have GLUE shares performed this year? Monte Rosa Therapeutics' stock was trading at $5.65 at the start of the year. Since then, GLUE shares have decreased by 17.3% and is now trading at $4.67. View the best growth stocks for 2024 here. How were Monte Rosa Therapeutics' earnings last quarter? Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) posted its earnings results on Thursday, May, 9th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.03. The business earned $1.06 million during the quarter, compared to analysts' expectations of $4.29 million. When did Monte Rosa Therapeutics IPO? Monte Rosa Therapeutics (GLUE) raised $211 million in an IPO on Thursday, June 24th 2021. The company issued 11,700,000 shares at $17.00-$19.00 per share. Who are Monte Rosa Therapeutics' major shareholders? Top institutional investors of Monte Rosa Therapeutics include Bank of New York Mellon Corp (0.22%). View institutional ownership trends. How do I buy shares of Monte Rosa Therapeutics? Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GLUE) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
